Filter Results


Study status

(for at least one location)



Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 58 for Multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study to Evaluate Daratumumab in Treating Transplant-Eligible Participants with Multiple Myeloma

    Jacksonville, FL

  2. A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  3. A Study to Evaluate APG2575 Combined with Novel Therapeutic Regimens To Treat Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis

    Jacksonville, FL

  4. Immune Monitoring and Immunotherapy in Myeloma

    Rochester, MN

  5. Assessing Glutamine Metabolism in MGUS and Myeloma

    Rochester, MN

  6. Trial of Sequential Treatment of Multiple Myeloma with Antibody Therapy

    Jacksonville, FL

  7. A Study to Evaluate Exercise for Cancer Patients at Risk of Falling

    Rochester, MN

  8. A Study to Evaluate Myeloma-Developing Regimens Using Genomics (MyDRUG)

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  10. A Study of Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Eau Claire, WI, Rochester, MN


Mayo Clinic Footer